There are tremendous opportunities for Canada. And I would say to Southeast Asia, and you heard me say this before, come to Canada. I mean, you know, we're here at the Milken Institute.We're talking about capital. So much of the capital today is talking about where is it that they can actually find places for global diversification. I would say Canada is a great place because the other thing we hear from so many of the capital investors here is they're looking for predictability.They're looking for countrie ...

Sticking with that trade front, President Trump says he's spoken to Indian Prime Minister Narendra Modi, in a move that could ease tensions between the two major economies. The call came after the two nations resumed trade negotiations. Let's get more with our senior editor, Derek Wallbank, joining us for more.I mean, Derek, I found it so interesting. You can see in that social media post that he said he had a wonderful call with India's Narendra Modi. But how did that become a wonderful call.When you look ...

Production & Trade - A significant portion of the company's product manufacturing is currently located in Mexico, benefiting from trade agreement exemptions [1] - The company is cautious and does not take current trade advantages for granted [1] - Shifting a substantial amount of production to America presents challenges, including costs, labor acquisition, and training, requiring a considerable timeframe exceeding one to two years [2] Pricing & Value Proposition - The company believes it currently possesses pricing power [1] - The company aims to maintain a strong value proposition for consumers [2] Brand & Identity - The company intends to stay true to its core identity, focusing on delivering high-quality products [3]

Core Insights - The pharmaceutical industry has historically been protected from tariffs due to long-standing trade agreements, but the current administration's focus on bringing manufacturing back to the U.S. poses new challenges [1][2] - President Trump has proposed tariffs of up to 25% on imported pharmaceuticals, with potential updates expected in early April [2] - The imposition of tariffs would represent a significant shift for the industry, reversing the effects of a 1994 World Trade Organization agreement that eliminated levies on many pharmaceutical products [3] Industry Impact - Analysts indicate that the pharmaceutical companies have benefited from low tax rates in countries like Ireland, which has attracted U.S. pharmaceutical firms [4] - The complexities of global tax strategies and supply chains may delay companies' ability to adjust to new tariffs, leading to potential negative impacts [5] - Companies such as Merck, AbbVie, Amgen, and Pfizer are identified as facing the highest risks from potential tariffs, while others like Eli Lilly and Gilead have more moderate risks [6]